An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.
clinicaltrials@alexion.com1-855-752-2356
Buenos Aires, Buenos Aires 1425, Argentina
CABA, Buenos Aires C1025ABI, Argentina
Ciudad de Buenos Aires, Buenos Aires F.D. C1181ACH, Argentina
Ciudad de Buenos Aires, C1428, Argentina
Montr Al, Quebec H1T 1C8, Canada
Montr Al, Quebec H2X 1R9, Canada
Praha, Central Bohemia 140 00, Czechia
Gie En, 35392, Germany
M Nchen, 81377, Germany
W Rzburg, 97078, Germany
Beer Yaakov, 70300, Israel
Kurume-shi, Fukuoka 830-0011, Japan
Matsumoto-shi, Nagano 390-8621, Japan
Suita-shi, Osaka 564-8565, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Lorenskog, N-1478, Norway
Santiago de Compostela-Coru A, Galicia 15706, Spain
Skellefte, Skelleftea 93186, Sweden
Taipei, Taipei 10002, Taiwan